JP7194022B2 - Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 - Google Patents
Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 Download PDFInfo
- Publication number
- JP7194022B2 JP7194022B2 JP2018560759A JP2018560759A JP7194022B2 JP 7194022 B2 JP7194022 B2 JP 7194022B2 JP 2018560759 A JP2018560759 A JP 2018560759A JP 2018560759 A JP2018560759 A JP 2018560759A JP 7194022 B2 JP7194022 B2 JP 7194022B2
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- cancer
- hydrate
- pharmaceutically acceptable
- pyrido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012271 PD-L1 inhibitor Substances 0.000 title claims description 50
- 229940121656 pd-l1 inhibitor Drugs 0.000 title claims description 50
- 239000012270 PD-1 inhibitor Substances 0.000 title description 34
- 239000012668 PD-1-inhibitor Substances 0.000 title description 34
- 229940121655 pd-1 inhibitor Drugs 0.000 title description 34
- 239000003112 inhibitor Substances 0.000 title description 6
- 238000002648 combination therapy Methods 0.000 title description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 77
- 238000011282 treatment Methods 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 43
- 201000011510 cancer Diseases 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 31
- 206010009944 Colon cancer Diseases 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 25
- YCBAQKQAINQRFW-UGSOOPFHSA-N 4,4,4-trifluoro-n-[(2s)-1-[[(7s)-5-(2-hydroxyethyl)-6-oxo-7h-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound OCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCC(F)(F)F)C)C2=CC=CC=C2C2=CC=CN=C21 YCBAQKQAINQRFW-UGSOOPFHSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 229950009791 durvalumab Drugs 0.000 claims description 18
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 16
- 229960003852 atezolizumab Drugs 0.000 claims description 16
- 229950002916 avelumab Drugs 0.000 claims description 16
- 208000029742 colonic neoplasm Diseases 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000001802 infusion Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000011260 co-administration Methods 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims 4
- 229940126062 Compound A Drugs 0.000 description 45
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 45
- 208000006990 cholangiocarcinoma Diseases 0.000 description 26
- 229960002621 pembrolizumab Drugs 0.000 description 18
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 17
- 229960003301 nivolumab Drugs 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 14
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 14
- 206010006187 Breast cancer Diseases 0.000 description 14
- 208000026310 Breast neoplasm Diseases 0.000 description 14
- 206010008342 Cervix carcinoma Diseases 0.000 description 14
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 14
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 14
- 208000036566 Erythroleukaemia Diseases 0.000 description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 14
- 208000000172 Medulloblastoma Diseases 0.000 description 14
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 14
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 14
- 206010061535 Ovarian neoplasm Diseases 0.000 description 14
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 14
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 14
- 206010060862 Prostate cancer Diseases 0.000 description 14
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 14
- 206010039491 Sarcoma Diseases 0.000 description 14
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 14
- 208000021841 acute erythroid leukemia Diseases 0.000 description 14
- 201000010881 cervical cancer Diseases 0.000 description 14
- 208000005017 glioblastoma Diseases 0.000 description 14
- 201000010536 head and neck cancer Diseases 0.000 description 14
- 208000014829 head and neck neoplasm Diseases 0.000 description 14
- 201000005202 lung cancer Diseases 0.000 description 14
- 208000020816 lung neoplasm Diseases 0.000 description 14
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 14
- 201000001441 melanoma Diseases 0.000 description 14
- 201000002528 pancreatic cancer Diseases 0.000 description 14
- 208000008443 pancreatic carcinoma Diseases 0.000 description 14
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 13
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 13
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 13
- 206010033128 Ovarian cancer Diseases 0.000 description 13
- 208000000453 Skin Neoplasms Diseases 0.000 description 13
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 13
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 13
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 13
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 13
- 201000007270 liver cancer Diseases 0.000 description 13
- 208000014018 liver neoplasm Diseases 0.000 description 13
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 13
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 13
- 201000000849 skin cancer Diseases 0.000 description 13
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 13
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 13
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 12
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 12
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 12
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 108010070047 Notch Receptors Proteins 0.000 description 10
- 102000005650 Notch Receptors Human genes 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000011664 signaling Effects 0.000 description 10
- 230000000996 additive effect Effects 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
- 102100022338 Integrin alpha-M Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 3
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 108091007744 Programmed cell death receptors Proteins 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000004323 axial length Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 231100000161 signs of toxicity Toxicity 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- TUCVAXGUCJNKBE-LIRRHRJNSA-N C(CCC)(=O)N[C@H](C(=O)N[C@@H]1C(N(C2=C(C3=C1C=CC=C3)C=CC=N2)CCO)=O)C Chemical compound C(CCC)(=O)N[C@H](C(=O)N[C@@H]1C(N(C2=C(C3=C1C=CC=C3)C=CC=N2)CCO)=O)C TUCVAXGUCJNKBE-LIRRHRJNSA-N 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001065556 Mus musculus Lymphocyte antigen 6G Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662339363P | 2016-05-20 | 2016-05-20 | |
| US62/339,363 | 2016-05-20 | ||
| PCT/US2017/032790 WO2017200969A1 (en) | 2016-05-20 | 2017-05-16 | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516733A JP2019516733A (ja) | 2019-06-20 |
| JP2019516733A5 JP2019516733A5 (enExample) | 2020-07-02 |
| JP7194022B2 true JP7194022B2 (ja) | 2022-12-21 |
Family
ID=58772978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560759A Active JP7194022B2 (ja) | 2016-05-20 | 2017-05-16 | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10688104B2 (enExample) |
| EP (1) | EP3458091B1 (enExample) |
| JP (1) | JP7194022B2 (enExample) |
| KR (1) | KR102463617B1 (enExample) |
| CN (2) | CN115845070A (enExample) |
| AU (1) | AU2017268187A1 (enExample) |
| BR (1) | BR112018073673A2 (enExample) |
| CA (1) | CA3025024A1 (enExample) |
| ES (1) | ES2904880T3 (enExample) |
| IL (1) | IL263110B (enExample) |
| MA (1) | MA45025A (enExample) |
| MX (1) | MX2018013941A (enExample) |
| SG (1) | SG11201810268YA (enExample) |
| WO (1) | WO2017200969A1 (enExample) |
| ZA (1) | ZA201807585B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| AU2016294440B2 (en) | 2015-07-13 | 2022-10-13 | Cytomx Therapeutics, Inc | Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof |
| US11564929B2 (en) | 2016-04-12 | 2023-01-31 | Eli Lilly And Company | Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer |
| KR102418765B1 (ko) | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법 |
| KR102463617B1 (ko) | 2016-05-20 | 2022-11-03 | 일라이 릴리 앤드 캄파니 | Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법 |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| KR20190116420A (ko) | 2017-02-17 | 2019-10-14 | 프레드 헛친슨 켄서 리서치 센터 | Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법 |
| CN111886012A (zh) | 2017-11-06 | 2020-11-03 | 朱诺治疗学股份有限公司 | 细胞疗法与γ分泌酶抑制剂的组合 |
| WO2019122998A1 (en) * | 2017-12-18 | 2019-06-27 | Debiopharm International Sa | Combination of an agonist anti-pd-1 antibody with a gnrh agonist or antagonist to treat cancer |
| KR20220114532A (ko) * | 2019-10-28 | 2022-08-17 | 주식회사 엔지켐생명과학 | 암의 치료를 위한 방법 및 조성물 |
| IL307974A (en) * | 2021-04-28 | 2023-12-01 | Obi Pharma Inc | Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| JP2014525918A (ja) | 2011-08-01 | 2014-10-02 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| JP2014527042A (ja) | 2011-07-27 | 2014-10-09 | イーライ リリー アンド カンパニー | ノッチ経路シグナリングインヒビター化合物 |
| WO2014193898A1 (en) | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| WO2015026634A1 (en) | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
| WO2015193352A1 (en) | 2014-06-17 | 2015-12-23 | Medimmune Limited | Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy |
| WO2016040880A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9711537B (en) | 1996-12-23 | 1998-06-25 | Athena Neurosciences Inc Eli L | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds. |
| JP2002526109A (ja) | 1998-10-02 | 2002-08-20 | ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ | アポトーシス誘導物質と方法 |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| GB0303663D0 (en) * | 2003-02-18 | 2003-03-19 | Lorantis Ltd | Assays and medical treatments |
| KR101498834B1 (ko) | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| HRP20080053A2 (hr) * | 2005-07-01 | 2009-08-31 | Medarex | Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1) |
| WO2007004743A1 (en) | 2005-07-05 | 2007-01-11 | Fujifilm Corporation | Copolymer and polymerizable composition |
| DE102006002966A1 (de) * | 2006-01-21 | 2007-07-26 | Schaeffler Kg | Laufscheibe mit integrierter Wälzkörperlaufbahn |
| WO2008112249A1 (en) | 2007-03-13 | 2008-09-18 | Trustees Of Columbia University In The City Of New York | Synergistic interaction of notch-1 inhibitors with glucocorticoids |
| EP2548558A1 (en) | 2007-03-28 | 2013-01-23 | Pharmacyclics, Inc. | Nitrogen-containing condensed heterocyclic as inhibitors of bruton's tyrosine kinase |
| CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
| BRPI0815135A2 (pt) | 2007-08-14 | 2015-02-03 | Lilly Co Eli | Derivados de azepina como inibidores de gama secretase. |
| RU2010133489A (ru) | 2008-01-11 | 2012-02-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Применение ингибиторов гамма-секретазы для лечения рака |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP5798919B2 (ja) | 2008-08-25 | 2015-10-21 | アンプリミューン、インコーポレーテッドＡｍｐｌｉｍｍｕｎｅ， Ｉｎｃ． | Ｐｄ−１アンタゴニストの組成物および使用方法 |
| CA3120172A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| US8741295B2 (en) | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
| WO2011026506A1 (de) | 2009-08-26 | 2011-03-10 | Frxsh Ag | Vorrichtung und verfahren zum mischen von mischgut |
| US8637493B2 (en) | 2009-11-12 | 2014-01-28 | University Of Massachusetts | Methods for treating glioblastoma |
| HUE037159T2 (hu) | 2009-11-24 | 2018-08-28 | Medimmune Ltd | Targetált kötõdõ ágensek B7-H1 ellen |
| CN102085372A (zh) | 2009-12-04 | 2011-06-08 | 中国医学科学院基础医学研究所 | Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途 |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| MX349096B (es) | 2011-11-28 | 2017-07-11 | Merck Patent Gmbh | Anticuerpos anti-pd-l1 y sus usos. |
| US9698876B2 (en) | 2013-07-23 | 2017-07-04 | Telefonaktiebolaget Lm Ericsson (Publ) | Transmission mode allocation in LTE networks |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| WO2015117164A1 (en) * | 2014-02-03 | 2015-08-06 | Memorial Sloan-Kettering Cancer Center | Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders |
| RU2017103289A (ru) | 2014-07-11 | 2018-08-14 | Дженентек, Инк. | Ингибирование пути notch |
| MX2017001011A (es) | 2014-07-21 | 2018-05-28 | Novartis Ag | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. |
| US9465158B2 (en) * | 2014-09-04 | 2016-10-11 | National Taiwan Normal University | Light-guide coupler for modulating angular and spatial distributions of light source |
| CA2965347C (en) * | 2014-10-27 | 2023-03-14 | Fred Hutchinson Cancer Research Center | Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy |
| MX382902B (es) * | 2014-10-31 | 2025-03-13 | Oncomed Pharm Inc | Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer. |
| RS61781B1 (sr) | 2014-12-05 | 2021-06-30 | Memorial Sloan Kettering Cancer Center | Antitela koja ciljaju antigen za sazrevanje b-ćelija i postupci upotrebe |
| EP3280795B1 (en) | 2015-04-07 | 2021-03-24 | Novartis AG | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| EP3662909A1 (en) | 2015-07-24 | 2020-06-10 | Oncotracker, Inc. | Gamma secretase modulators for the treatment of immune system dysfunction |
| US11564929B2 (en) | 2016-04-12 | 2023-01-31 | Eli Lilly And Company | Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer |
| KR102418765B1 (ko) | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법 |
| KR102463617B1 (ko) | 2016-05-20 | 2022-11-03 | 일라이 릴리 앤드 캄파니 | Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법 |
| CN116473978A (zh) | 2016-08-31 | 2023-07-25 | 伊莱利利公司 | 用于治疗实体瘤的给药方案 |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| CN111886012A (zh) | 2017-11-06 | 2020-11-03 | 朱诺治疗学股份有限公司 | 细胞疗法与γ分泌酶抑制剂的组合 |
-
2017
- 2017-05-16 KR KR1020187036486A patent/KR102463617B1/ko active Active
- 2017-05-16 IL IL263110A patent/IL263110B/en unknown
- 2017-05-16 AU AU2017268187A patent/AU2017268187A1/en not_active Abandoned
- 2017-05-16 ES ES17726073T patent/ES2904880T3/es active Active
- 2017-05-16 WO PCT/US2017/032790 patent/WO2017200969A1/en not_active Ceased
- 2017-05-16 MX MX2018013941A patent/MX2018013941A/es unknown
- 2017-05-16 SG SG11201810268YA patent/SG11201810268YA/en unknown
- 2017-05-16 EP EP17726073.4A patent/EP3458091B1/en active Active
- 2017-05-16 CA CA3025024A patent/CA3025024A1/en active Pending
- 2017-05-16 CN CN202211692364.1A patent/CN115845070A/zh active Pending
- 2017-05-16 BR BR112018073673-2A patent/BR112018073673A2/pt unknown
- 2017-05-16 US US16/301,360 patent/US10688104B2/en active Active
- 2017-05-16 MA MA045025A patent/MA45025A/fr unknown
- 2017-05-16 CN CN201780044786.9A patent/CN109475629A/zh active Pending
- 2017-05-16 JP JP2018560759A patent/JP7194022B2/ja active Active
-
2018
- 2018-11-12 ZA ZA2018/07585A patent/ZA201807585B/en unknown
-
2020
- 2020-05-08 US US16/870,853 patent/US11826317B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| JP2014527042A (ja) | 2011-07-27 | 2014-10-09 | イーライ リリー アンド カンパニー | ノッチ経路シグナリングインヒビター化合物 |
| JP2014525918A (ja) | 2011-08-01 | 2014-10-02 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| WO2014193898A1 (en) | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| WO2015026634A1 (en) | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
| WO2015193352A1 (en) | 2014-06-17 | 2015-12-23 | Medimmune Limited | Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy |
| WO2016040880A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
Non-Patent Citations (2)
| Title |
|---|
| LIPSON, Evan J. et al.，Clinical Cancer Research，2013年01月15日，Vol. 19, Issue 2，pp. 462-468，https://doi.org/10.1158/1078-0432.CCR-12-2625 |
| 聖マリアンナ医科大学雑誌，2016年，Vol.43，pp.237-243 |
Also Published As
| Publication number | Publication date |
|---|---|
| MA45025A (fr) | 2019-03-27 |
| MX2018013941A (es) | 2019-03-21 |
| AU2017268187A1 (en) | 2018-11-29 |
| US20190192531A1 (en) | 2019-06-27 |
| KR20190008913A (ko) | 2019-01-25 |
| US11826317B2 (en) | 2023-11-28 |
| EP3458091B1 (en) | 2021-11-17 |
| CN109475629A (zh) | 2019-03-15 |
| IL263110A (en) | 2018-12-31 |
| KR102463617B1 (ko) | 2022-11-03 |
| BR112018073673A2 (pt) | 2019-02-26 |
| US10688104B2 (en) | 2020-06-23 |
| ZA201807585B (en) | 2024-09-25 |
| CA3025024A1 (en) | 2017-11-23 |
| EP3458091A1 (en) | 2019-03-27 |
| CN115845070A (zh) | 2023-03-28 |
| JP2019516733A (ja) | 2019-06-20 |
| SG11201810268YA (en) | 2018-12-28 |
| IL263110B (en) | 2022-07-01 |
| ES2904880T3 (es) | 2022-04-06 |
| WO2017200969A1 (en) | 2017-11-23 |
| US20220008432A1 (en) | 2022-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7194022B2 (ja) | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 | |
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP7445893B2 (ja) | ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ | |
| JP2022044767A (ja) | 癌を処置する方法 | |
| US20240254120A1 (en) | Ep4 inhibitors and synthesis thereof | |
| US12295962B2 (en) | Polymorphic compounds and uses thereof | |
| CA2672933A1 (en) | Method of treating cancer by a combined therapy of anticancer agents | |
| JP2023533485A (ja) | 重症型の肺高血圧症の治療方法 | |
| JP2025185043A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| AU2019362050B2 (en) | Combinations for immune-modulation in cancer treatment | |
| JP2023542093A (ja) | 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用 | |
| JP2025516885A (ja) | ニロガセスタットを用いた治療 | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| JP2015514796A (ja) | ２から３０ｍｇ／ｋｇの範囲の用量で癌を治療するのに使用するためのデキサナビノールまたはこの誘導体 | |
| JP7504106B2 (ja) | がんの処置のための組合せ物 | |
| HK40004756A (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| HK40004756B (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| RU2774721C2 (ru) | Применение комбинированного лечения на основе антитела к PD-1 и апатиниба для лечения трижды негативного рака молочной железы | |
| WO2020205458A1 (en) | Combination therapy to treat cancer and uses thereof | |
| CN120346313A (zh) | 治疗肿瘤的药物组合 | |
| NZ788180A (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200518 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200518 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210518 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210817 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211018 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220405 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220705 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220905 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221005 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221122 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221209 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7194022 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |